Screening for Hemoglobinopathies in Pregnant Women
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Gabriela Amstad Bencaiova, Dr. med
- Phone Number: 0041 61 556 5922
- Email: gabriela.amstad@usb.ch
Study Contact Backup
- Name: Irene Hoesli, Prof. Dr.
- Phone Number: 0041 61 265 9017
- Email: irene.hoesli@usb.ch
Study Locations
-
-
-
Basel, Switzerland, 4031
- Frauenklinik University Hospital Basel
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- pregnant women seen at the Frauenklinik at University Hospital Basel
Exclusion Criteria:
- pregnant women with already known hemoglobinopathy
- refusal of participation
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
identification of hemoglobinopathies
Time Frame: single time point assessment at baseline
|
identification of hemoglobinopathies by investigating routine lab samples
|
single time point assessment at baseline
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Irene Hoesli, Prof. Dr., Frauenklinik Universitätsspital Basel
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2019-01065; sp19Amstad
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hemoglobinopathies
-
NCT07190001Not yet recruitingHemoglobinopathies (Transfusion-dependent β-thalassemia and Sickle Cell Disease)
-
NCT04798157Not yet recruitingHemoglobinopathies
-
NCT06646640Recruiting
-
NCT05184647Not yet recruiting
-
NCT05286138Recruiting
-
NCT00481260Completed
-
NCT07579949Not yet recruiting
-
NCT07207551Completed
Clinical Trials on Review of routine lab data
-
NCT04788394CompletedCoronavirus Infection | Covid19 | Renal Insufficiency | AKI | Acute Kidney Injury | Pediatric Kidney Disease | Renal Dysfunction
-
NCT06304727Recruiting
-
NCT06244420Completed
-
NCT04960020CompletedAnterior Cruciate Ligament Tear
-
NCT03479359UnknownProstatic Neoplasms | Benign Prostatic Hyperplasia | Digital Rectal Examination
-
NCT05641584CompletedInflammation | Aortic Valve Stenosis | HDL
-
NCT03082170UnknownSleep Apnea, Obstructive | Dysphagia
-
NCT06220071CompletedSpinal Metastases